ଲୁମାଟେପେରୋନ

ଲୁମାଟେପେରୋନ
Clinical data
Pronunciation	/luːməˈtɛpərɑːn/; loo-MƏ-TE-PƏ-ron; Caplyta kəp-LY-tə
Trade names	Caplyta
Synonyms	Lumateperone tosylate, ITI-007; ITI-722
AHFS/Drugs.com	monograph
MedlinePlus	a620014
data	US DailyMed: Lumateperone;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	4.4%
Protein binding	97.4%
Metabolism	Multiple UGTs, CYP450s, and AKR enzymes
Excretion	<1% excreted unchanged in urine
Identifiers
	IUPAC name 1-(4-Fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-butanone;
Chemical and physical data
Formula	C24H28FN3O
Molar mass	୩୯୩.୫୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C;

ଲୁମାଟେପେରୋନ, ଏକ ବିକ୍ରୟ ନାମ କ୍ୟାପଲିଟା, ଏକ ଔଷଧ ଯାହା ସିଜୋଫ୍ରେନିଆ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିଦ୍ରାଳୁ ଭାବ ଏବଂ ଶୁଖିଲା ପାଟି ହୋଇପାରେ ।^[୨] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନ୍ୟୁରୋଲେପ୍ଟିକ ମାଲିଗନାଣ୍ଟ ସିଣ୍ଡ୍ରୋମ, ଟାର୍ଡିଭ ଡିସକାଇନେସିଆ, ମଧୁମେହ, ଓଜନ ବୃଦ୍ଧି, ସ୍ୱଳ୍ପ ଶ୍ୱେତ ରକ୍ତ କଣିକା, ବାତ ଓ ସମନ୍ୱୟ ଅଭାବ ହୋଇପାରେ । ^[୧] ଡିମେନ୍ସିଆ ରୋଗୀଙ୍କ କ୍ଷେତ୍ରରେ ଏହା ମୃତ୍ୟୁ ଆଶଙ୍କା ବଢ଼େଇଥାଏ ।^[୧] ଏହା ଏକ ଆଟିପିକାଲ୍ ଆଣ୍ଟିସାଇକୋଟିକ ଶ୍ରେଣୀର ଔଷଧ ।^[୧]

୨୦୧୯ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଏହି ଲୁମାଟେପେରୋନ ଔଷଧ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ମାସକୁ ଏହି ଔଷଧ ବାବଦ ପ୍ରାୟ ୧୪୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୩]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ "Caplyta- lumateperone capsule". DailyMed. Intra-Cellular Therapies, Inc. 27 December 2019. Archived from the original on 4 July 2020. Retrieved 3 July 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Lumateperone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 January 2021. Retrieved 24 November 2021.
↑ "Lumateperone Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 24 November 2021.

[PI2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ "Caplyta- lumateperone capsule". DailyMed. Intra-Cellular Therapies, Inc. 27 December 2019. Archived from the original on 4 July 2020. Retrieved 3 July 2020.

[AHFS2021-2] ୨.୦ ^୨.୧ ^୨.୨ "Lumateperone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 January 2021. Retrieved 24 November 2021.

[3] "Lumateperone Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 24 November 2021.

[୨]

[୧]

[୩]

Clinical data

Pronunciation	/luːməˈtɛpərɑːn/ loo-MƏ-TE-PƏ-ron Caplyta kəp-LY-tə
Trade names	Caplyta
Synonyms	Lumateperone tosylate, ITI-007; ITI-722
AHFS/Drugs.com	monograph
MedlinePlus	a620014
data	US DailyMed: Lumateperone
Routes of administration	By mouth
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	4.4%^[୧]
Protein binding	97.4%^[୧]
Metabolism	Multiple UGTs, CYP450s, and AKR enzymes^[୧]
Excretion	<1% excreted unchanged in urine^[୧]
Identifiers
IUPAC name 1-(4-Fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-butanone
Chemical and physical data
Formula	C₂₄H₂₈FN₃O
Molar mass	୩୯୩.୫୧ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES [H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C